Peptris Technologies Private
Bangalore, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $8.4M
Overview
AI-driven drug discovery company using proprietary generative AI to design novel molecules and repurpose drugs for oncology, inflammation, and rare diseases.
OncologyInflammationRare Diseases
Technology Platform
Proprietary AI platform integrating unsupervised learning and generative AI with a novel molecule language syntax to design novel chemical entities, repurpose drugs, and rescue clinical candidates.
Opportunities
Growing global demand for AI-driven drug discovery solutions, expansion into additional therapeutic areas beyond current focus, and potential for more licensing deals as pipeline assets mature.
Risk Factors
Preclinical stage pipeline with unproven clinical efficacy, dependency on CRO partners for experimental validation, and intense competition from well-funded global AI drug discovery companies.
Competitive Landscape
Competes with global AI drug discovery platforms like Exscientia, Recursion, and Insilico Medicine, but differentiates through its virtual model, focus on the Indian market, and three-pronged approach targeting novel molecules, repurposing, and clinical candidate rescue.